← The Wire
CRSPNasdaq
CRISPR Therapeutics AG
Biological Products, (No Diagnostic Substances) · V8 · CIK 1674416
Develops CRISPR-based gene therapies for serious human diseases
red 8-K · 90d⚡ Elevated coverage
$4.90B
Market cap
$56.35
Last close
+2.6%
1D
+3.7%
5D
1.8M
Volume
Price · last 39 sessions+5.2%
May 4L $47.59 · H $56.95Jun 29
230
Total filings
Jun 4, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Bylaw AmendmentJun 4, 202610-Q10-QMay 4, 20268-KResults of OperationsMay 4, 2026DEFA14ADEFA14AApr 21, 2026DEF 14ADEF 14AApr 21, 20268-KMaterial Agreement · New Debt / ObligationMar 16, 20268-KCompany UpdateMar 11, 202610-K10-KFeb 12, 20268-KResults of OperationsFeb 12, 20268-KCompany UpdateJan 12, 202610-Q10-QNov 10, 20258-KResults of OperationsNov 10, 20258-KCompany UpdateOct 15, 2025424B5424B5Oct 15, 202510-Q10-QAug 4, 20258-KResults of OperationsAug 4, 20258-KCompany UpdateJun 26, 20258-KBylaw Amendment · Shareholder VoteJun 9, 2025424B5424B5May 19, 20258-KMaterial Agreement · Company UpdateMay 19, 202510-Q10-QMay 6, 20258-KResults of OperationsMay 6, 2025DEFA14ADEFA14AApr 16, 2025DEF 14ADEF 14AApr 16, 20258-KExecutive ChangeMar 26, 202510-K10-KFeb 11, 20258-KResults of OperationsFeb 11, 202510-Q10-QNov 5, 20248-KResults of OperationsNov 5, 202410-Q10-QAug 5, 20248-KResults of OperationsAug 5, 20248-KExecutive Change · Bylaw AmendmentJun 3, 20248-KExecutive ChangeMay 23, 202410-Q10-QMay 8, 20248-KResults of OperationsMay 8, 2024DEFA14ADEFA14AApr 9, 2024DEF 14ADEF 14AApr 9, 202410-K10-KFeb 21, 20248-KResults of OperationsFeb 21, 20248-KMaterial AgreementFeb 13, 2024424B5424B5Feb 13, 20248-KCompany UpdateFeb 13, 20248-KCompany UpdateJan 16, 20248-KExecutive ChangeDec 19, 20238-KCompany UpdateDec 15, 20238-KMaterial AgreementDec 13, 20238-KCompany UpdateDec 8, 20238-KCompany UpdateDec 4, 20238-KCompany UpdateNov 16, 202310-Q10-QNov 6, 20238-KResults of OperationsNov 6, 20238-KExecutive Change · Company UpdateSep 7, 202310-Q10-QAug 7, 20238-KResults of OperationsAug 7, 20238-KExecutive Change · Bylaw AmendmentJun 9, 20238-KReg FD Disclosure · Company UpdateJun 9, 2023DEFA14ADEFA14AMay 18, 202310-Q10-QMay 8, 20238-KResults of OperationsMay 8, 2023DEFA14ADEFA14AApr 26, 2023DEF 14ADEF 14AApr 26, 20238-KReg FD Disclosure · Company UpdateApr 3, 20238-KExecutive ChangeMar 29, 20238-KMaterial Agreement · Reg FD DisclosureMar 27, 20238-KExecutive ChangeMar 14, 202310-K10-KFeb 21, 20238-KResults of OperationsFeb 21, 2023SC 13GSEC SCHEDULE 13GFeb 13, 202310-Q10-QNov 1, 20228-KResults of OperationsNov 1, 20228-KExecutive ChangeOct 27, 20228-KReg FD Disclosure · Company UpdateSep 27, 202210-Q10-QAug 8, 20228-KResults of OperationsAug 8, 20228-KCompany UpdateJun 21, 20228-KExecutive Change · Bylaw AmendmentJun 13, 20228-KReg FD Disclosure · Company UpdateJun 13, 20228-KReg FD DisclosureMay 16, 20228-KReg FD Disclosure · Company UpdateMay 12, 202210-Q10-QMay 9, 2022
Insider Activity
In the 90 days to Mar 23, 2026: 4 sold $12.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 23, 2026 | Kulkarni SamarthChief Executive Officer | Sell | 10,020 | $46.78 | $469K |
| Mar 23, 2026 | Prasad RajuChief Financial Officer | Sell | 3,708 | $46.78 | $173K |
| Mar 23, 2026 | Kasinger James R.General Counsel and Secretary | Sell | 3,182 | $46.78 | $149K |
| Mar 16, 2026 | Kulkarni SamarthChief Executive Officer | Sell | 10,349 | $48.26 | $499K |
| Mar 16, 2026 | Prasad RajuChief Financial Officer | Sell | 5,848 | $48.26 | $282K |
| Mar 16, 2026 | Prasad RajuChief Financial Officer | Sell | 4,021 | $48.26 | $194K |
| Mar 16, 2026 | Kasinger James R.General Counsel and Secretary | Sell | 3,450 | $48.26 | $166K |
| Mar 16, 2026 | Patel NaimishChief Medical Officer | Sell | 3,150 | $48.26 | $152K |
| Mar 11, 2026 | Kulkarni SamarthChief Executive Officer | Sell | 9,798 | $52.80 | $517K |
| Mar 11, 2026 | Kasinger James R.General Counsel and Secretary | Sell | 2,800 | $52.80 | $148K |
| Feb 19, 2026 | Kulkarni SamarthChief Executive Officer | Sell | 6,967 | $52.58 | $366K |
| Feb 19, 2026 | Kasinger James R.General Counsel and Secretary | Sell | 2,112 | $52.58 | $111K |
| Jan 22, 2026 | Kulkarni SamarthChief Executive Officer | Sell | 60,000 | $60.23 | $3.6M |
| Jan 22, 2026 | Prasad RajuChief Financial Officer | Sell | 34,972 | $60.19 | $2.1M |
| Jan 20, 2026 | Kulkarni SamarthChief Executive Officer | Sell | 21,433 | $51.61 | $1.1M |
| Jan 20, 2026 | Kulkarni SamarthChief Executive Officer | Sell | 8,567 | $52.10 | $446K |
| Jan 6, 2026 | Prasad RajuChief Financial Officer | Sell | 18,933 | $60.18 | $1.1M |
| Jan 6, 2026 | Prasad RajuChief Financial Officer | Sell | 5,763 | $60.21 | $347K |
| Jan 6, 2026 | Prasad RajuChief Financial Officer | Sell | 5,004 | $60.00 | $300K |
| Dec 22, 2025 | Prasad RajuChief Financial Officer | Sell | 5,472 | $56.33 | $308K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 1 reputable article · skews ▲ positive.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance